Collateral sensitivity to cisplatin in KB-8-5-11 drug-resistant cancer cells

Ben Doherty, Denise Lawlor, Jean-Pierre Gillet, Michael Gottesman, John J O'Leary, Britta Stordal

Research output: Contribution to journalArticlepeer-review


BACKGROUND: KB-8-5-11 cells are a drug-resistant cervical cell model that overexpresses ABCB1 (P-glycoprotein). KB-8-5-11 has become sensitive to non-ABCB1 substrate cisplatin. Understanding the mechanism of collateral sensitivity to cisplatin may lead to biomarker discovery for platinum sensitivity in patients with cancer.

MATERIALS AND METHODS: A Taqman low-density array was used to characterize the expression of 380 genes previously associated with chemoresistance. Identified pathways were further analyzed using cytotoxicity assays, metabolomics and western blots.

RESULTS: KB-8-5-11 cells were sensitive to CuSO4 and the glutathione inhibitor buthionine sulphoximine. Expression of ATPase, Cu(2+) transporting alpha (ATP7A) and ATP7B were decreased at the protein and gene levels respectively in KB-8-5-11. KB-8-5-11 had decreased gene expression of glutathione S-transferase pi 1 (GSTP1), GSTA4 and GSTK1. Cisplatin treatment significantly lowered total cellular glutathione in parental KB-3-1 cells. Glutathione also tended to be lower in KB-8-5-11 cells compared to KB-3-1 cells.

CONCLUSION: KB-8-5-11 cells have alterations in their copper transporters and glutathione metabolism, contributing to their cisplatin-sensitive phenotype.

Original languageEnglish
Pages (from-to)503-7
Number of pages5
JournalAnticancer Research
Issue number1
Publication statusPublished - 2014


  • Cervical cancer
  • Cisplatin
  • Collateral sensitivity
  • Drug resistance
  • KB-8-5-11 cells
  • Paclitaxel


Dive into the research topics of 'Collateral sensitivity to cisplatin in KB-8-5-11 drug-resistant cancer cells'. Together they form a unique fingerprint.

Cite this